Bcl-2 antisense therapy in B-cell malignant proliferative disorders

Current Treatment Options in Oncology
Asher Chanan-Khan, Myron S Czuczman

Abstract

Overexpression of Bcl-2 oncogene has been clinically associated with an aggressive clinical course, chemotherapy and radiotherapy resistance, and poor survival in patients with malignant B-cell disorders. Patients with relapsed or refractory chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin's lymphoma have limited therapeutic options. Preclinical and early clinical data have shown that Bcl-2 oncoprotein can be decreased by Bcl-2 antisense therapy. Also, downregulation of Bcl-2 protein can result in reversal of chemotherapy resistance and improved antitumor activity of biologic agents. Various clinical trials are evaluating the role of targeting Bcl-2 as a mechanism to enhance the antitumor potential of chemotherapy and immunotherapy. Early results from these clinical studies are encouraging and confirm the proof of principle for antisense therapy. As current data mature, these trials will hopefully validate preliminary results and establish Bcl-2 antisense as an important addition to the current armamentarium used in the treatment of patients with B-cell neoplasms.

References

Jan 23, 1999·Oncogene·J C Reed
Apr 29, 1999·International Journal of Radiation Oncology, Biology, Physics·M D LogsdonT J McDonnell
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S WatersF E Cotter
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·I Lebedeva, C A Stein
May 24, 2003·The Hematology Journal : the Official Journal of the European Haematology Association·Yuan Zhang, Xiao Yong Lei
Jun 11, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A WunderlichUNKNOWN German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
Feb 1, 2002·Seminars in Oncology·Michael J KeatingMaher Albitar

❮ Previous
Next ❯

Citations

Mar 17, 2005·World Journal of Urology·Alan SoColleen Nelson
May 17, 2005·Nitric Oxide : Biology and Chemistry·Karsten HemmrichVictoria Kolb-Bachofen
May 5, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Elizabeth J MeredithJohn Gordon
Jun 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alessio NencioniAlberto Ballestrero

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.